navitoclax

Term ID

CHEBI:131174

Synonyms

4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide
A-855071.0
ABT 263
ABT-263
ABT263
navitoclax
navitoclaxum

(all 7)

Definition

A N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. Currently under clinical investigation as treatment for solid tumors and hematologic malignancies.

References

(all 36)

Ontology

ChEBI ( EBI )

Relationships

is a type of: aryl sulfide monochlorobenzenes morpholines N-sulfonylcarboxamide organofluorine compound ... Show All 9 Terms

aryl sulfide monochlorobenzenes morpholines N-sulfonylcarboxamide organofluorine compound piperazines secondary amino compound sulfone tertiary amino compound Show first 5 Terms
has_role: antineoplastic agent apoptosis inducer B-cell lymphoma 2 inhibitor

antineoplastic agent apoptosis inducer B-cell lymphoma 2 inhibitor Show first 5 Terms

Phenotype

Phenotype resulting from navitoclax

Phenotype where environments contain navitoclax

Phenotype modified by environments containing navitoclax

Phenotype affecting navitoclax

Human Disease Model